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Abstract 
Aims: Radiofrequency-based electrophysical agents (EPAs) have been used in therapy 
practice over several decades (e.g. shortwave therapies). Currently there is insufficient 
evidence supporting such EPAs operating below shortwave frequencies. This laboratory-
based study investigated the deep physiological effects of 448 kHz capacitive resistive 
monopolar radiofrequency (CRMRF) and compared them to pulsed shortwave therapy 
(PSWT). Methods: In a randomised crossover study, seventeen healthy volunteers initially 
received four treatment conditions – High, Low and Placebo dose conditions receiving 15-
minute CRMRF treatment and a Control condition receiving no intervention. Fifteen 
participants additionally received high dose PSWT as fifth condition, for comparison. Pre and 
post treatment measurements of deep blood flow and tissue extensibility were obtained using 
Doppler ultrasound and Sonoelastography. Group data were compared using ANOVA model. 
Statistical significance was set at p≤0.05, 0.8 power, and 95% CI. Results: Significant 
increases in volume and intensity of deep blood flow were obtained with CRMRF over 
placebo, control (p=0.003) and PSWT (p<0.001). No significant changes in blood flow 
velocity or tissue extensibility were noted for any condition. Conclusions: Deep blood flow 
changes with CRMRF were more pronounced than that with PSWT, placebo or control. 
Potential greater therapeutic benefits need to be confirmed with comparative clinical studies. 
Key words 
Deep blood flow; Electrophysical agents; Physiological effects; PSWT; 448 kHz 
radiofrequency; Tissue extensibility. 
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Introduction 
The efficacy of electrophysical agents (EPAs) used in therapy practice is underpinned by 
their ability to influence the body’s physiological mechanisms, thereby affecting the 
underlying pathological processes. Ultimately, this can lead to effects such as reduction in 
pain and inflammation, acceleration of tissue healing and overall improvements in function 
(1, 2). Several of these benefits relate to thermophysiological responses in the body such as 
changes to blood flow, muscle tone and tissue compliance achieved primarily through 
induced tissue hyperthermia (3-6). 
The physical nature and metabolic state of tissues can be altered by changes in blood flow 
and tissue extensibility, and thereby provide the therapeutic benefits either directly or create a 
tissue environment that enables the clinician to deliver treatment more effectively in patients 
and in non-clinical situations (such as in an athlete recovering from muscle fatigue). For 
example, increasing the compliance of tight soft tissue structures will enable the therapist to 
stretch them more effectively and gain improved range of movement (7, 8). Increasing 
muscle blood flow may potentially aid faster recovery from post exercise fatigue. In 
physiotherapy, radiofrequency (RF)-based EPAs are among those that claim to increase blood 
flow as well as improve soft tissue compliance, mainly by inducing tissue hyperthermia (9-
15). Measures relating to blood flow and tissue compliance closely reflect the body’s 
response when tissues are exposed to heat, with the radiofrequency energy potentially 
capable of inducing a hyperthermic effect at depth (16-18). 
Abnormalities in blood flow have an overarching relationship to pathological states and their 
treatment; hence an accurate measurement of blood flow without interfering with the 
circulatory process itself is imperative. A relative change in the local blood flow can 
characterise a variety of physiological states, either normal or pathological. For example, an 
increase in local blood flow may be noticed when there is tissue inflammation (19, 20). When 
localised radiofrequency treatment is administered, monitoring of the blood flow can help in 
determining how much heating will occur in the tissues. Hence, it enables a protective 
regulatory mechanism ensuring that there is no undue tissue hyperthermia (21, 22). 
The RF frequency ranges used in physiotherapy are largely limited to 30 kHz–30 MHz (23-
26). Within this range the main EPA used is shortwave therapy (SWT), which commonly 
operates at 27.12 MHz, either in continuous (CSWT) or pulsed (PSWT) mode although it is 
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largely limited to PSWT in contemporary practice (25, 27). SWT is also the most widely 
researched radiofrequency-based EPA. Nonetheless, EPAs employing significantly lower 
frequency RFs (<1 MHz) have also been reported in therapy practice, despite their evidence 
base being minimal. An example for such an EPA is Capacitive Resistive Monopolar 
Radiofrequency (CRMRF) that employs radiofrequency at 448 kHz. This mode of therapy is 
relatively new, but is reported to be available and used by clinicians worldwide as a safe form 
of electrophysical therapy. Similar to SWT, the particular frequency employed relates to 
international guidelines rather than reported optimum efficacy. 
The CRMRF differs from SWT mainly in two ways – firstly the operating frequency, which 
is significantly smaller than the shortwaves and secondly, unlike SWT it cannot be delivered 
to the target tissues through an air gap. Hence, a coupling medium similar to ultrasound gel 
that acts as a conductor is used to transmit the energy. The inability of CRMRF to transmit 
through air may act as a potential advantage over SWT since scattering of the CRMRF waves 
will be considerably lower. Without the need for a special conducting medium, shortwave 
devices are known to emit stray radiations in the air (1, 28). Therefore some of the shortwave 
energy will be lost through scattering, making it difficult to concentrate the delivery in the 
required area treated (29, 30). 
In this study the authors aimed to investigate the deep blood flow and tissue extensibility 
responses to continuous-mode CRMRF therapy in asymptomatic adults and compare them to 
those obtained with PSWT. Similar studies involving only SWT that were conducted on 
either asymptomatic subjects (12, 14, 15, 31) or patient groups (10, 32, 33) have been 
reported previously. However, to our knowledge this will be the first in vivo study that 
investigated the deep physiological responses to RF exposure below the shortwave frequency 
band. 
Although CRMRF is a continuous mode therapy unlike PSWT, comparison of these two 
EPAs was done on the basis that PSWT is the most relevant comparator to CRMRF in 
contemporary therapy environment. The clinical use of CSWT has decreased significantly in 
the western world over the recent decades (25, 27). Currently, no data is available from the 
literature comparing the two EPAs. Since CRMRF was shown to substantially increase and 
sustain skin temperature in our previously reported study (16), it was hypothesised that 
similar significant effects may be obtained on deep blood flow and tissue extensibility. The 
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results of this study are expected to provide important insight into the mode of action of low 
frequency RF-based EPAs such as CRMRF that has largely remained unexplored (23, 26). 
Materials and Methods 
Study design 
The aims of the study were investigated in a crossover study conducted in the physiotherapy 
research laboratory of the University of Hertfordshire on 17 asymptomatic (self-reported) 
adults. 
Sample and groups 
The participants were randomly recruited via emails from the 27,000 members of the 
University of Hertfordshire. They all had normal skin thermal perception and no contra-
indications to radiofrequency-based therapy. Each of the 17 participants attended four 
sessions using a randomised crossover design, representing four experimental conditions – 
CRMRF high (thermal), CRMRF low (sub/minimally thermal) and CRMRF placebo dose 
conditions, and a control condition with no intervention (Figure 1). The order of attendance 
was randomised using a computer generated randomisation chart (IBM SPSS Statistics, 
Version 20), and concealed blinded from the participants. Fifteen participants additionally 
attended a fifth session representing ‘PSWT high dose’ condition to enable a comparison 
between the two EPAs. Attendance to PSWT condition was not randomised, and hence not 
truly blinded although they were only informed that it was another type of RF. The study was 
approved by the Health and Human Sciences Ethics Committee with Delegated Authority 
(HHSECDA) of the University of Hertfordshire (Protocol number: cHSK/PG/UH/00143). All 
participants signed an informed consent prior to the study. 
**Insert Figure 1 here** 
Apparatus 
CRMRF device 
The CRMRF energy at 448 kHz was delivered using ‘Indiba Activ 902’ (Indiba S. A., 
Barcelona). This therapeutic device was factory calibrated and pretested for accuracy of 
output. The peak power of the device was 200 Watts (W) (or 450 Volt-Ampere (VA)). It 
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delivers continuous-wave radiofrequency energy in two modes: A ‘capacitive (CAP) mode’ 
and a ‘resistive (RES) mode’, using metallic electrodes via a coupling medium. 
PSWT device 
PSWT was delivered using ‘Bosch Ultramed’ (Robert Bosch GmbH, Germany) that operates 
at 27.12 MHz. The pulse duration (PD) was fixed at 400 µs, repeating at (pulse repetition 
rate; PRR) 15–200 Hz. The peak power (PP) can be varied from 100 to 1000 Watts (W). The 
desired mean power (MP) can be obtained by manipulating these pulse parameters. The 
device was calibrated prior to the study. 
Doppler ultrasound and Sonoelastography 
Blood flow to the deeper tissues (two centimetres or more from the skin) was monitored 
using Doppler ultrasound that provided information on the velocity, volume and intensity of 
blood flow. The indices of tissue extensibility (measurements of relative hardness/softness of 
tissues) were obtained using Sonoelastography. An ‘Esaote MyLab70 XVG’ (Esaote S.p.A, 
Genoa, Italy) ultrasound scanner was used alongside a linear array probe ‘LA523’ that 
supports a frequency range of 4–13 MHz (Esaote S.p.A, Genoa, Italy) to collect the data. 
Sample ultrasound images obtained from one of the participants are shown in Figure 2. 
**Insert Figure 2 here** 
Other devices 
Blood pressure (BP) and pulse rate (PR) were monitored using a digital BP monitor (Omron 
M2, Omron Healthcare Europe B.V., Netherlands) and core temperature using an infra-red 
(IR) tympanic thermometer (Braun ThermoScan IRT 4520, Braun GmbH, Germany). A body 
composition monitor (Omron BF508, Omron Healthcare Europe B.V., Netherlands) was used 
to obtain the anthropometric data. Room temperature and humidity were monitored using an 
electronic thermohygrometer (RS 212-124, RS Components Pte Ltd., Singapore). 
Experimental procedure and Data acquisition 
The participants were asked to avoid food, beverages and strenuous exercises before the start 
of sessions to minimise physiological inconsistencies. They attended one treatment condition 
per session in a random order. A minimum gap of 48 hours was ensured between sessions. 
Similar times (±1 hour) of the day were chosen for all sessions of a participant. The 
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participants were screened using an eligibility questionnaire including questions relating to 
any recent injury or illness and accepted contraindications to RF therapy (pregnancy, 
malignancy, metal or electronic implants in the body). Subsequently, their ‘skin thermal 
sensitivity’ and the ability to distinguish between warm and cold was tested using test tubes 
filled with water at approximately three different temperatures (±0.5 oC): 45 oC (warm), 35 
oC (neutral) and 25 oC (cold). After this screening, demographic and anthropometric data 
were collected. 
Participants were then positioned in supine after changing to shorts or other loose fitting 
clothes. The skin over the medial aspect of both thighs were prepared and marked. While the 
skin and experimental setting was being prepared the participants acclimatised for 20 minutes 
in supine. For all participants the right leg was chosen for the study, while the untreated left 
leg served as control. Blood flow and Sonoelastography measurements were performed pre 
and post intervention. Core temperature, BP and PR were also concurrently monitored. For 
each participant, blood flow was identified by manoeuvring the ultrasound probe over the 
lower anteromedial aspect of the quadriceps femoris muscle. Once most prominent pulsatile 
(arterial) flow was identified, skin markings were used to maintain accuracy of probe 
placement and ensure repeatability. For Sonoelastography measurements, a fixed probe 
position was adopted for all participants. The probe was placed parallel to the longitudinal 
axis of thigh, perpendicular to the skin in the middle lower part of the marked area. Minimal 
probe pressure and liberal amount of conductive gel were used to avoid any undue 
compression of the tissues. 
For all participants, the machine settings remained the same for both pre and post treatment 
measurements. Data clips were recorded up to five seconds for both Doppler and 
Sonoelastography measurements during each assessment, which were then broken down into 
image frames for analysis. Prior to this study, intra-rater reliability for both Doppler and 
Sonoelastography measurements was established in a pilot study on 12 participants. The 
ICCs (3,1) for all measurements relating to blood flow (Doppler) were 0.818 – 0.987 with 
95% CI, and within 0.957 – 0.998 with 95% CI for all measurements relating to tissue 
compliance (Elastography). 
Radiofrequency Intervention 
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The CRMRF treatment was delivered for 15 minutes (5 minutes in CAP mode followed by 
10 minutes in RES mode) using 20 ml coupling medium for each mode. The return plate 
electrode was smeared with 20 ml coupling medium and positioned under the calf muscle 
belly. The dosage was adjusted based on participant feedback. For CRMRF high, the 
intensity was gradually increased till the participants reported moderate yet comfortable 
heating, which was then maintained throughout the session. For CRMRF low, the intensity 
was maintained at a sub/minimally-thermal level throughout. For CRMRF placebo, the 
device output was turned off after the participants reported thermal onset (within the first 
minute). For the control condition the participants rested on the treatment plinth for 15 
minutes. The nearest available PSWT dose to the mean CRMRF high dose (42.37 W) used in 
this study was 47 W (PD–400 µs, PRR–200 Hz, PP–600 W). Hence, 47 W was delivered for 
15 minutes to all 15 participants who attended PSWT group, using a drum (monode) 
applicator placed 1.5 cm from the skin. 
Data Analysis 
Ultrasound images were computationally analysed using MATLAB (MathWorks, 
Massachusetts) algorithms to process the colour image data into numerical data. For every 
image frame the MATLAB algorithms generated two types of data: the ‘pixel count’ (total 
number of coloured pixels) in the ‘region of interest’ (ROI) indicating the blood volume 
information, and the ‘colour intensity index’ (sum of colour intensity values of all the 
coloured pixels in the ROI). In the final analysis, the pixel count was expressed in ‘kilo 
pixels’ (pixel count divided by 1000) and the colour intensity index as the ‘mean colour 
intensity index per pixel’ by dividing the sum of colour intensity values of a frame by the 
total number of pixels in that frame. In colour Doppler, the ‘colour intensity index’ indicated 
the relative velocity of blood flow, where higher the index higher was the velocity. In power 
Doppler, the pixel count represented the overall ‘blood volume’ and the colour intensity 
index represented the ‘blood flow intensity’. Higher the pixel count and/or index, higher were 
the blood flow. The degree of tissue compliance (level of hardness/softness) data from 
Sonoelastography was analysed similarly to the Doppler data although the MATLAB 
algorithms varied depending on the machine colour scales and their pixel values. The analysis 
of all machine colour scales using MATLAB is further illustrated in Figure 3. 
All data were analysed using IBM SPSS Statistics ((Version 20) IBM Corporation, USA). 
Two separate data analyses, with three CRMRF and control groups (17 participants) and with 
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all five groups (15 participants) were undertaken. The data sets from all five experimental 
conditions were tested for normal distribution. To ascertain any statistically significant 
differences between conditions, group data were compared using either two-way 
(intervention and time) repeated measures analysis of variance (ANOVA) at two time points 
(baseline, post treatment) or using the non-parametric alternative Friedman’s two-way 
ANOVA by ranks, where the data sets violated the assumptions of normality (Shapiro-Wilk 
test). Statistical significance was set at p ≤ 0.05 (0.8 P, 95% CI). A post-hoc analysis was 
conducted using G*Power (Version 3.1) to determine the power. 
**Insert Figure 3 here** 
Results 
All participants completed the treatments and the accompanying assessments. Both types of 
interventions were well tolerated, with no reports of any adverse events. The demographic 
and mean (SD) anthropometric data are reported in Table 1. Mean (SD) treatment doses, 
room temperature and humidity are reported in Table 2. The study was conducted in 
thermoneutral conditions. To illustrate the levels of variation among participants, the 
individual dosage data from the three radiofrequency groups are plotted in Figure 4. 
**Insert Table 1 here** 
**Insert Table 2 here** 
**Insert Figure 4 here** 
Blood Flow Volume 
Figures 5(a–b) shows the mean (SD) blood flow volumes recorded at the two time points and 
the percentage changes of mean. 
**Insert Figures 5a & 5b here** 
Blood flow volume data were analysed by Friedman’s two-way ANOVA by ranks. In the 
four-group analysis, a significant main effect for the interventions was found at post 
treatment [2 (3) = 13.659, p=0.003]. Therefore, the applied dose influenced the changes in 
blood flow volume. At baseline the groups did not differ significantly, except between the 
control and placebo groups (Friedman, p=0.009). In the five-group analysis similar result was 
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obtained for the main effect [2 (4) = 20.000, p<0.001]. The five groups were not 
significantly different at baseline. 
Within the CRMRF high group there was a substantial rise in blood flow volume from 
baseline to post treatment (Wilcoxon, p=0.001, r=0.60). A significant increase, although less 
strong was noted also in the CRMRF low group (Wilcoxon, p=0.006, r=0.47). No such 
meaningful changes in blood flow volume were noted in the other three groups. Key results 
of pairwise comparisons between groups are reported in Table 3. 
**Insert Table 3 here** 
Blood Flow Intensity 
Figures 6(a–b) shows the mean (SD) blood flow intensities recorded at the two time points 
and the percentage changes of mean. 
**Insert Figures 6a & 6b here** 
Blood flow intensity data were analysed by Friedman’s two-way ANOVA by ranks. In the 
four-group analysis, a significant main effect for the interventions was found at post 
treatment [2 (3) = 14.788, p = 0.002]. Therefore, the applied dose influenced the changes in 
blood flow volume. At baseline the groups did not differ significantly. In the five-group 
analysis similar result was obtained for the main effect [2 (4) = 18.240, p=0.001]. The five 
groups were not significantly different at baseline. 
Within the CRMRF high group there was a substantial rise in blood flow intensity from 
baseline to post treatment (Wilcoxon, p=0.001, r=0.55). No such meaningful changes were 
noted in the blood flow intensity recordings of the other four groups. Key results of pairwise 
comparisons between groups are reported in Table 4. 
**Insert Table 4 here** 
Blood Flow Velocity and Tissue Extensibility 
No significant main effects, interactions or changes within groups were noted for any of the 
intervention groups for any time point in either the four or the five-group analysis for blood 
flow velocity and the tissue extensibility measures. 
Other results 
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No significant variations were ever noted in core temperature, BP or PR under any test 
condition. 
The post-hoc analysis revealed that the overall power obtained for both statistical analyses on 
blood flow volume and intensity were over 80%. 
Discussion 
Although numerous studies have investigated the effects of radiofrequency-based treatment 
in animal models as well as in humans, there is insufficient evidence to demonstrate the 
effects of radiofrequency below the shortwave frequency band. Two recent reviews on the 
use of radiofrequency-based EPAs in therapy-related clinical practice published by the same 
authors found no clinical studies on acute conditions for frequencies below shortwave (23) 
and only a limited number of such studies on chronic conditions (26). The current study 
addressed the issue of physiological effects of both types of frequency ranges of RF by 
performing due comparisons between CRMRF that operates at 448 kHz in continuous mode 
and PSWT that operates at 27 MHz in pulsed mode. 
Recently, the skin thermal responses to incremental doses of CRMRF were reported by us in 
an experimental study (16). The current study reports other thermophysiological responses 
such as changes in deep blood flow as well as changes in tissue compliance (up to over two 
cm depths from the skin), in response to the application of multiple doses of CRMRF therapy 
and a comparable high dose of PSWT. In terms of the mode of energy delivery PSWT may 
not be directly comparable to CRMRF since the former is pulsed while the latter is 
continuous. Besides, PSWT is not known to cause extremely high thermophysiological 
responses due to a “washout” of the heat energy from the tissues during its “off cycle”. 
However, the comparisons have been made for the aforementioned reasons.  
The within-group changes (the changes within each experimental condition) in tissue 
response and the results of the between-group pair-wise comparisons (the comparisons 
between the experimental conditions) reported in tables 3 and 4 show that a high dose of 
CRMRF can significantly increase the blood flow volume (effect size, r = 0.60) and the blood 
flow intensity (r = 0.55) in deeper tissues. Although less significant, even a low dose of 
CRMRF can increase the blood flow volume at depth (r = 0.47). In contrast, exposure to an 
equivalent high dose of PSWT failed to induce any such effects on either the volume or the 
intensity of blood flow in deeper tissues. Either type of RF failed to significantly increase the 
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blood flow velocity. Since similar studies that employed RF at frequencies lower than 
shortwave have not been reported previously, the authors are unable to make any direct 
comparison with existing literature. 
Studies in the past have suggested that the differences in blood flow responses secondary to 
electromagnetic field (EMF) exposure are mainly due to the differences in their ability to 
penetrate tissues and the level of rise in local tissue temperature. Radiofrequency-based EPAs 
are proposed to be more penetrative and are anticipated to influence blood flow at various 
depths (9, 12, 16) compared to low penetrative infrared radiation (IRR) that has been shown 
to increase cutaneous circulation (34, 35). Previous research with shortwave has proposed 
that a tissue temperature rise to levels in excess of 40 oC may be necessary to increase muscle 
blood flow (36). Temperature of the tissues was not directly monitored in the current study; 
however, it is unlikely to have risen to levels above 40 oC. Skin temperature responses 
secondary to CRMRF exposure has already been reported by us (16). The peak temperature 
attained by Kumaran and Watson (2015)  that used much higher CRMRF doses than those 
reported in this study was below 40 oC (16).  
Hence, extrapolating our previous findings to the results of this study it may be argued that 
the significant rise in deep blood flow volume and flow intensity obtained with the high dose 
CRMRF might have been achieved with a potentially modest rise in tissue temperature. This 
is further vindicated by the rise in blood flow volume even with the low dose CRMRF where 
the rise in tissue temperature must have been minimal. This potentially suggests that a 
substantial rise in tissue temperature may not be required for CRMRF to achieve increased 
deep blood flow. Moreover, it needs to be taken into account that the Doppler measurements 
were only able to be recorded about five minutes after the end of the intervention owing to 
the skin preparation time and the time taken to locate blood flow, which meant that any blood 
flow responses during and immediately after the treatment were not accounted for. Therefore, 
based on the current and previously reported (16) results on CRMRF and the existing 
shortwave literature (36), it is proposed that unlike SWT the CRMRF may be capable of 
increasing and sustaining blood flow at depth at substantially lower tissue temperatures. This 
suggests that CRMRF is potentially capable of inducing a sustained influence on the 
physiological processes relating to deep blood flow with mechanisms that are either thermal 
or nonthermal or both. 
13 
 
Considering the above argument, it is implied that compared to CRMRF a substantially 
higher dose of treatment and hence a substantially higher amount of energy (potentially 
generating a high thermal response as explained) may be needed for PSWT to produce effects 
similar to that of CRMRF. In other words, PSWT may lack any notable nonthermal effect on 
deep blood flow in the absence of significant tissue heating. This is justified by the mixed 
reports on the deep circulatory effect of PSWT available from the literature (15, 37), which 
indicate that when compared to the doses in this study; a substantially higher dose of PSWT 
may be required to increase blood flow at depth. In fact, PSWT was designed to deliver 
pulsed RF energy to provide physiological benefits without an undue rise in tissue 
temperature. It appears from the results of this study that a low dose CRMRF can potentially 
achieve the same benefits more effectively than PSWT without unduly raising the tissue 
temperature despite being a continuous-mode RF therapy. It is therefore assumed that the 
type of applied energy might also be a critical factor beside the temperature change, in 
deciding the level of tissue response. 
With regards to tissue extensibility, early work has shown that heat changes the behaviour of 
collagenous tissues making it more viscoelastic (38, 39), and reduces spasm in muscles (40). 
However, for a notable effect, the tissue temperature will need to be raised at least to the level 
of 40 oC (41). Contrary to blood flow, there were no significant effects on tissue extensibility 
with any of the interventions in this study. Nonetheless, it may be noted that the 
Sonoelastography measurements were performed after the blood flow measurements were 
taken, thus any effect during or immediately after the intervention should clearly have been 
missed. This clearly is a limitation of this study. Besides, all participants in this study had 
normal muscle tone with no concomitant injury. People affected by conditions that may be 
compromising their tissue extensibility, or even asymptomatic people who are presented with 
increased tone in their muscles could behave differently to the subjects of this study. 
The results also indicate a dose-response relationship, with the high dose CRMRF inducing a 
more pronounced physiological response than the low dose CRMRF. The mean dose 
delivered to the high dose group was twice as that of the low dose group. In addition, there 
were small variations in dosage within the groups itself as a fixed dose was not delivered to 
every participant in the group (dosing varied based on the participants’ thermal perception 
and thermal tolerance). Since only two active doses of CRMRF were employed, 
recommendations on the optimum dosage parameters could not be identified. It has also not 
been possible to identify why some participants were able to receive a higher dose of 
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CRMRF when compared to the others. It is proposed that the thermal sensory perception of 
the individual may have been responsible for the level of energy uptake. The thermal 
perception is a normally distributed phenomenon in a normative sample. Additional studies 
will need to be carried out to further identify the dosage and other intervention parameters. 
Although the study used a crossover design employing participants with a wide age range 
(25–66 years, with a mean (SD) age of 45.71 (12.70) years) and varying physical activity 
levels, there were several study limitations too. Besides the short delay in obtaining the post 
treatment data, there were no follow-up assessments and the physiological responses during 
the intervention phase were not mapped, unlike in some of the previous shortwave studies 
(13, 14, 37) where peripheral blood flow was monitored during the intervention. The PSWT 
session was not randomised, not fully blinded and was always the fifth session for all 
participants. Also, the study was only single-blind as the researcher (BK) who performed the 
interventions and assessments remained unblinded. Together, the above factors may 
somewhat limit the validity of the findings. Future studies should be fully randomised, 
double-blinded, employ follow-ups and minimise the time delay in starting the post treatment 
measurements. Additionally, to facilitate a full understanding of the physiological responses, 
the measurements should be enabled during the treatment delivery where possible. 
Conclusions 
The results of this study suggest that a high as well as low dose of CRMRF can significantly 
enhance blood flow volume at depth, while only the high dose can enhance both the volume 
and intensity of flow. An equivalent high dose of PSWT failed to show any impact on either 
parameter, which meant that overall CRMRF induced a significantly more pronounced 
physiological response out of the two types of radiofrequency-based EPAs. None of the 
treatment conditions had any impact on the deep blood flow velocity. The extensibility of 
tissues (relative hardness and softness), core temperature, BP and PR were not affected by 
either type of RF treatment. 
Based on the presented results the hypothesis proposed on the effects of CRMRF on deep 
blood flow was accepted, but not for tissue extensibility. The more pronounced physiological 
effects of CRMRF in healthy participants compared to PSWT may be indicative of its 
potentially greater clinical benefits; however, caution should be exercised in extrapolating 
these findings to patient populations who could respond differently to the same intervention. 
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Further studies that address the limitations of this study, that explore additional physiological 
responses and clinical studies that involve patient groups are therefore necessary. 
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Table 1: Demographic and mean (±SD) anthropometric data from the 17 participants who 
received localised 448 kHz Capacitive Resistive Monopolar Radiofrequency (CRMRF) 
treatment. 
 
Sample 
Demographic data Mean (±SD) anthropometric data 
Mean 
(±SD) age 
(years) 
Gender: 
Males 
Gender: 
Females 
Height 
(m) 
Weight 
(kg) 
Body fat 
(%) 
Visceral 
fat 
BMI 
17 
45.71 
(12.70) 
7 10 
1.70 
(0.08) 
71.48 
(10.02) 
30.32 
(7.61) 
7.24 
(2.54) 
24.68 
(2.71) 
 
SD – standard deviation; kg – kilogram; m – metre; BMI – body mass index. 
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Table 2: Mean (±SD) treatment doses received by the participants in the five experimental 
groups, and mean (±SD) room temperature and humidity during the experimental sessions. 
 
 
CRMRF 
High 
CRMRF 
Low 
CRMRF 
Placebo 
Control PSWT 
RF dosage in 
Watts (W) 
42.37 
(4.64) 
18.77 
(3.82) 
2.79 
(1.23) 
0 47 
Room 
temperature (oC) 
25.12 
(1.14) 
25.53 
(1.11) 
25.35 
(1.06) 
25.18 
(1.04) 
24.30 
(0.56) 
Humidity (%) 
41.21 
(6.38) 
41.06 
(7.40) 
39.68 
(6.24) 
41.79 
(6.50) 
32.70 
(4.37) 
 
CRMRF – Capacitive Resistive Monopolar Radiofrequency; PSWT – Pulsed Shortwave 
Therapy; RF – radiofrequency. 
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Table 3: Key results from the pairwise comparisons on blood flow volume responses across 
the five experimental groups. 
Comparisons involving PSWT group are based on 15 participants, while all others are based 
on 17 participants. Data were not significantly different at baseline, except between the 
placebo and control groups. Statistical significance was set at p ≤ 0.05 (Friedman’s two-way 
ANOVA). 
 
Comparison 
Test 
statistic 
Adjusted 
significance 
value (p) 
Effect size 
(r) 
Power 
(P) 
CRMRF high vs.  CRMRF low 0.353 1.000 (NS) 0.137  
CRMRF placebo 1.176 0.047 0.456 0.815 
Control 1.412 0.009 0.547 0.920 
PSWT 2.067 0.003 0.654 0.961 
CRMRF low vs.  CRMRF placebo 0.824 0.377 (NS) 0.319  
Control 1.059 0.101 (NS) 0.410  
PSWT 1.867 0.012 0.590 0.924 
PSWT vs. CRMRF placebo 0.600 1.000 (NS) 0.190  
Control 0.467 1.000 (NS) 0.148  
 
CRMRF – Capacitive Resistive Monopolar Radiofrequency; PSWT – Pulsed Shortwave 
Therapy; NS – non-significant. 
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Table 4: Key results from the pairwise comparisons on the blood flow intensities across five 
experimental groups. 
Comparisons involving PSWT group are based on 15 participants, while all others are based 
on 17 participants. Data were not significantly different at the baseline. Statistical 
significance was set at p ≤ 0.05 (Friedman’s two-way ANOVA). 
 
Comparison 
Test 
statistic 
Adjusted 
significance 
value (p) 
Effect size 
(r) 
Power 
(P) 
CRMRF high vs.  CRMRF low 0.471 1.000 (NS) 0.182  
CRMRF placebo 0.824 0.377 (NS) 0.319  
Control 1.647 0.001 0.638 0.972 
PSWT 2.000 0.005 0.632 0.951 
CRMRF low vs.  CRMRF placebo 0.353 1.000 (NS) 0.137  
Control 1.176 0.047 0.456 0.815 
PSWT 1.467 0.111 (NS) 0.464  
PSWT vs. CRMRF placebo 0.800 1.000 (NS) 0.253  
Control 0.067 1.000 (NS) 0.020  
 
CRMRF – Capacitive Resistive Monopolar Radiofrequency; PSWT – Pulsed Shortwave 
Therapy; NS – non-significant. 
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Figure 1: Schematic representation of the five study groups. Groups 1–4 were represented by all 17 participants, with each participant assigned 
a random order of attendance. Group 5 was represented by 15 participants only, at non-random and was always the last (fifth) session. 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Sample images 
showing the Doppler 
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Ultrasound and Ultrasound Elastography recordings from one participant (Number 14) before and after receiving the ‘CRMRF high’ 
intervention. 
The data shown are: Colour Doppler images showing the peak velocity of blood flow (top left), Power Doppler images showing the peak volume 
and peak intensity of blood flow (bottom left), and Elastography images showing the hard, intermediate and soft tissue structures (right). The 
images were computationally analysed using MATLAB codes (MathWorks, Massachusetts, USA) to convert the colour image data into 
numerical data. 
 
 
 
 
 
 
 
 
Pre-intervention Post intervention 
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Figure 3: Images (left) and graphs (right) showing the analysis of colour Doppler (top), power Doppler (middle) and Elastography (bottom) 
colour scales. For colour and power Doppler, a linear relation was identified between the intensity of colour on the scale and the amount of 
‘green’ component (as plotted) of the corresponding RGB (red, green and blue) spectrum. Red and blue components did not follow this linear 
relation and were hence not used for the analysis of either colour or power Doppler. The x-axis shows the ‘pixels’ from the top to the bottom of 
the scale on the left and the y-axis shows the corresponding value of ‘green’ from the RGB scores. For Elastography, which was divided into 
‘hard’, ‘intermediate’ and ‘soft’ categories, all three colour components (red, blue and green respectively) were analysed and used for 
interpretation as shown in the graph. 
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Figure 4: Data from CRMRF high, CRMRF low and PSWT high groups, showing the individual treatment doses delivered. 
Participants 9 & 10 did not attend the PSWT group. 
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Figure 5a: The mean (±SD) deep blood flow volume responses showing the baseline and post treatment data from all five groups. 
The PSWT group results are based on 15 participants, while the other four groups’ results are based on 17 participants. Statistically significant 
differences (at p ≤ 0.05) when compared to the baseline are indicated by asterisks (*) above the error bars (Friedman’s two-way ANOVA). 
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Figure 5b: Percentage change of the mean deep blood flow volume from baseline to post treatment for all five groups. 
The PSWT group results are based on 15 participants, while the other four groups’ results are based on 17 participants. Statistically significant 
differences (at p ≤ 0.05) when the groups were compared pairwise are given in Table 3 (Friedman’s two-way ANOVA). 
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Figure 6a: The mean (±SD) deep blood flow intensity responses showing the baseline and post treatment data from all five groups. 
The PSWT group results are based on 15 participants, while the other four groups’ results are based on 17 participants. Statistically significant 
differences (at p ≤ 0.05) when compared to the baseline are indicated by asterisks (*) above the error bars (Friedman’s two-way ANOVA).  
29 
 
 
 
 
 
 
 
 
 
 
Figure 6b: Percentage change of the 
mean deep blood flow intensity from baseline to post treatment for all five groups. 
The PSWT group results are based on 15 participants, while the other four groups’ results are based on 17 participants. Statistically significant 
differences (at p ≤ 0.05) when the groups were compared pairwise are given in Table 4 (Friedman’s two-way ANOVA). 
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